CLOROQUINA E HIDROXICLOROQUINA COMO OPÇÕES PARA TRATAR A COVID-19

CHLOROCHINE AND HYDROXYCHLOROCHINE AS OPTIONS TO TREAT COVID-19

Autores/as

  • Maria Luana de Freitas Rabelo Graduanda em Farmácia pela Universidade Federal do Ceará (UFC).

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet [Internet]. 2020;395(10224):565–74. Disponível em: <http://dx.doi.org/10.1016/S0140-6736(20)30251-8>.

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–6.

Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients with COVID-19. JAMA - J Am Med Assoc. 2020;323(15):1499–500.

Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source . These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active . The anti-viral facet of anti-rheumatic drugs : Lessons from COVID-19. 2020;(January).

Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol [Internet]. 2020;16(3):155–66. Disponível em: <http://dx.doi.org/10.1038/s41584-020-0372x>.

Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018;41(10):919–31.

Al-Bari AA. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2014;70(6):1608–21.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (London, England) [Internet]. 2020;6736(20):1–10. Disponível em: <http://www.ncbi.nlm.nih.gov/pubmed/32450107>.

Publicado

2020-07-22

Cómo citar

1.
de Freitas Rabelo ML. CLOROQUINA E HIDROXICLOROQUINA COMO OPÇÕES PARA TRATAR A COVID-19: CHLOROCHINE AND HYDROXYCHLOROCHINE AS OPTIONS TO TREAT COVID-19. Cadernos ESP [Internet]. 22 de julio de 2020 [citado 3 de julio de 2024];14(1):176-7. Disponible en: https://cadernos.esp.ce.gov.br/index.php/cadernos/article/view/371
Recibido 2020-05-30
Aceptado 2020-07-22
Publicado 2020-07-22